US Stocks Movement: Moderna surges on October 9, included in Nasdaq 100 + Cancer Vaccine
Bitget异动解读2026/10/09 14:05Moderna’s Surge on October 9: An Analysis
Keywords: Included in Nasdaq-100, Cancer Vaccine
1. On October 9, Moderna was officially included in the Nasdaq-100 Index, replacing Warner Bros. Discovery; this index is tracked by more than 200 investment products with assets under management exceeding 800 billion USD.
2. On October 7, the company, together with Merck and Tempus, expanded their multi-year partnership to support tumor sample collection, sequencing, as well as therapy design and production for the potential commercialization of the personalized neoantigen therapy intismeran autogene.
3. On October 7, Morgan Stanley raised Moderna’s target price from 89 USD to 95 USD; the company’s phase III study for personalized cancer therapy in partnership with Merck has achieved its primary endpoint of recurrence-free survival, and five-year data shows a 49% reduction in recurrence or death risk compared to Keytruda monotherapy.
(Disclaimer: This content is collected and summarized from publicly available information by AI technology. It is for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US Stock Movement | Snap (SNAP.US) rises over 6% as hedge funds urge the introduction of external capital for Specs, potentially unlocking shareholder value
According to news from Zhitong Finance APP, on Friday, Snap (SNAP.US) surged over 6% to $6.24. On the news front, the hedge fund Blue Duck Capital Partners hopes that Snap Inc. will sell part of its Specs business shares to raise funds. Alex Beinfield, Chief Investment Officer of Blue Duck, recently said in a letter to Snap’s board that Snap is "seriously" undervalued, and raising funds for Specs would unlock significant shareholder value. He stated that a financing centered on Specs would help support related expenditures without diluting Snap's share count, while also preserving its cash flow. Moreover, this move is expected to help the company reduce the Specs’ price of about $2,200. He believes that selling 20% of the Specs subsidiary at a valuation of $5 billion would raise $1 billion, enough to support that department's expenses for around two years.
AI data center company Firmus, backed by Nvidia (NVDA.US), cancels IPO amid doubts over its $30 billion valuation and insufficient demand from U.S. investors
According to Zhihui Finance APP, Firmus Grid, an Australian artificial intelligence (AI) data center operator backed by Nvidia (NVDA.US), originally planned to go public with a valuation of around 30 billions USD, which would have made it one of Australia's largest initial public offerings (IPO). However, due to overvaluation, insufficient investor subscription demand, and concerns in the market regarding the massive financing needs of AI infrastructure, this high-profile IPO was ultimately canceled on Friday.
Crypto prices
More
